Clinical Trial Update: Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for AZD4547 as second-line therapy in FGFR-positive recurrent stage IV squamous cell lung cancer (Phase 2/Phase 3) completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Lung Cancer
• Squamous Cell Lung Carcinoma

Drugs mentioned

• AZD4547

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: FGFR1 Gene Amplification, FGFR1 Gene Mutation | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-05-27